Immunocore Holdings ( (IMCR) ) has shared an update.
On March 10, 2025, Immunocore Holdings announced initial data from the Phase 1/2 STRIVE trial of IMC-M113V, a functional cure candidate for HIV, presented at the CROI 2025 conference. The data showed that IMC-M113V was well tolerated with signals of dose-dependent viral control after antiretroviral treatment interruption, marking a significant step in HIV treatment. The trial continues to evaluate higher doses, with potential implications for reducing lifelong antiretroviral treatment for people living with HIV.
More about Immunocore Holdings
Immunocore Holdings is a commercial-stage biotechnology company that develops TCR bispecific immunotherapies, known as ImmTAX, to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. The company is advancing clinical candidates for functional cures for HIV and hepatitis B virus (HBV) and has a deep pipeline in multiple therapeutic areas.
YTD Price Performance: -0.07%
Average Trading Volume: 267,107
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.49B
Learn more about IMCR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com